1462 related articles for article (PubMed ID: 15323591)
1. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
2. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
Feiger AD; Heiser JF; Shrivastava RK; Weiss KJ; Smith WT; Sitsen JM; Gibertini M
J Clin Psychiatry; 2003 Mar; 64(3):243-9. PubMed ID: 12716264
[TBL] [Abstract][Full Text] [Related]
3. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
4. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.
Amsterdam JD; Brunswick DJ; Gibertini M
J Psychiatr Res; 2004; 38(3):259-65. PubMed ID: 15003431
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms.
Sramek JJ; Tansman M; Suri A; Hornig-Rohan M; Amsterdam JD; Stahl SM; Weisler RH; Cutler NR
J Clin Psychiatry; 1996 Jul; 57(7):287-91. PubMed ID: 8666569
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
7. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients.
Wilcox CS; Ferguson JM; Dale JL; Heiser JF
Psychopharmacol Bull; 1996; 32(3):335-42. PubMed ID: 8961776
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
[TBL] [Abstract][Full Text] [Related]
9. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
Feiger AD
Psychopharmacol Bull; 1996; 32(4):659-65. PubMed ID: 8993088
[TBL] [Abstract][Full Text] [Related]
10. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
Fawcett J; Marcus RN; Anton SF; O'Brien K; Schwiderski U
J Clin Psychiatry; 1995; 56 Suppl 6():37-42. PubMed ID: 7649972
[TBL] [Abstract][Full Text] [Related]
11. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
Tollefson GD; Holman SL; Sayler ME; Potvin JH
J Clin Psychiatry; 1994 Feb; 55(2):50-9. PubMed ID: 8077155
[TBL] [Abstract][Full Text] [Related]
13. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety.
Fawcett J; Barkin RL
J Clin Psychiatry; 1998 Mar; 59(3):123-7. PubMed ID: 9541155
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
16. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home.
Roose SP; Nelson JC; Salzman C; Hollander SB; Rodrigues H;
Curr Med Res Opin; 2003; 19(8):737-46. PubMed ID: 14687445
[TBL] [Abstract][Full Text] [Related]
17. Buspirone in the management of major depression: a placebo-controlled comparison.
Fabre LF
J Clin Psychiatry; 1990 Sep; 51 Suppl():55-61. PubMed ID: 2211570
[TBL] [Abstract][Full Text] [Related]
18. Paroxetine versus placebo: a double-blind comparison in depressed patients.
Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
[TBL] [Abstract][Full Text] [Related]
19. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
Rickels K; Mathew S; Banov MD; Zimbroff DL; Oshana S; Parsons EC; Donahue SR; Kauffman M; Iyer GR; Reinhard JF
J Clin Psychopharmacol; 2008 Apr; 28(2):235-9. PubMed ID: 18344738
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
